Evidence map›Paper›PMID 34493586›Full record

Observational studyInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society2021

Vulvar cancer in Botswana in women with and without HIV infection: patterns of treatment and survival outcomes.

Emily MacDuffie, Sruthi Sakamuri, Rebecca Luckett, Qiao Wang, Memory Bvochara-Nsingo, Barati Monare, Lisa Bazzett-Matabele, Thabo Moloi, Tlotlo Ralefala, Doreen Ramogola-Masire and 3 more

Open access · greenAbstract readObservational Study
In one paragraph

Observational study in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Emily MacDuffie *Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Sruthi Sakamuri *Department of Obstetrics and Gynecology, Pennsylvania Hospital, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Rebecca LuckettBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Qiao WangSue and Bill Gross School of Nursing, University of California, Irvine, California, USA.
Memory Bvochara-NsingoDepartment of Oncology, Gaborone Private Hospital, Gabarone, Botswana.
Barati MonareBotswana-UPenn Partnership, Gaborone, Botswana.
Lisa Bazzett-MatabeleDepartment of Obstetrics and Gynecology, University of Botswana, Gaborone, Botswana.
Thabo MoloiPrincess Marina Hospital, Gaborone, Botswana.
Tlotlo RalefalaPrincess Marina Hospital, Gaborone, Botswana.
Doreen Ramogola-MasireDepartment of Obstetrics and Gynecology, Pennsylvania Hospital, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Sanghyuk S ShinSue and Bill Gross School of Nursing, University of California, Irvine, California, USA.
Nicola M ZetolaDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Surbhi GroverDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA surbhi.grover@uphs.upenn.edu.
Botswana Harvard AIDS Institute Partnership · BWUniversity of Pennsylvania · USUniversity of Botswana · BWUniversity of California, Irvine · USBotswana Open University · BWPennsylvania Hospital · US

Funding

Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI DAVID S METZGER · 1999 to 2026
$78.6M
Prognostic value of quantitative HPV viral load in determining cervical cancer treatment response and recurrenceK08CA230170 · NCI · UNIVERSITY OF PENNSYLVANIA · PI GROVER, SURBHI · 2019 to 2023
$1.4M
NCI NIH HHS K08 CA230170NIAID NIH HHS P30 AI045008
6 · The paper itself

Abstract

objectivesVulvar cancer is a rare gynecological malignancy. However, the incidence of human papillomavirus (HPV)-associated vulvar disease is increasing, particularly in low- and middle-income countries. HIV infection is associated with an increased risk of HPV-associated vulvar cancer. We evaluated treatment patterns and survival outcomes in a cohort of vulvar cancer patients in Botswana. The primary objective of this study was to determine overall survival and the impact of treatment modality, stage, and HIV status on overall survival.

methodsWomen with vulvar cancer who presented to oncology care in Botswana from January 2015 through August 2019 were prospectively enrolled in this observational cohort study. Demographics, clinical characteristics, treatment, and survival data were collected. Factors associated with survival including age, HIV status, stage, and treatment were evaluated.

resultsOur cohort included 120 women with vulvar cancer. Median age was 42 (IQR 38-47) years. The majority of patients were living with HIV (89%, n=107) that was well-controlled on antiretroviral treatment. Among women with HIV, 54.2% (n=58) were early stage (FIGO stage I/II). In those without HIV, 46.2% (n=6) were early stage (stage I/II). Of the 95 (79%) patients who received treatment, 20.8% (n=25) received surgery, 67.5% (n=81) received radiation therapy, and 24.2% (n=29) received chemotherapy, either alone or in combination. Median follow-up time of all patients was 24.7 (IQR 14.2-39.1) months and 2- year overall survival for all patients was 74%. Multivariate analysis demonstrated improved survival for those who received surgery (HR 0.26; 95% CI 0.08 to 0.86) and poor survival was associated with advanced stage (HR 2.56; 95% CI 1.30 to 5.02). Survival was not associated with HIV status.

conclusionsThe majority of women with vulvar cancer in Botswana are young and living with HIV infection. Just under half of patients present with advanced stage, which was associated with worse survival. Improved survival was seen for those who received surgery.

Indexed as

AdultAntiviral AgentsBotswanaCase-Control StudiesCoinfectionFemaleHIV InfectionsHumansKaplan-Meier EstimateMiddle AgedPapillomavirus InfectionsProspective StudiesVulvar NeoplasmsAntiviral Agentsvulvar neoplasms

Identifiers

PMID34493586
PMCPMC8675890
OpenAlexW3197172152

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.